Why It Matters
WelbeHealth filed a new client registration on Tuesday, August 13, 2026, marking its formal entry into federal lobbying. The healthcare organization is registered as an in-house lobbying operation and has engaged external lobbying firms to advance its advocacy agenda.
WelbeHealth's lobbying registration signals the organization's commitment to shaping federal healthcare policy. By establishing an in-house operation alongside external counsel, the company positioned itself to directly influence debates over healthcare delivery, pharmacy regulations, and technology standards.
By The Numbers
WelbeHealth's lobbying team evolved throughout 2025 and into 2026. The organization initially engaged Venn Strategies LLC, paying $70,000 in quarter one of 2025 and $50,000 in quarter two of 2025 before terminating that relationship on May 14, 2025. The company then shifted to BGR Government Affairs LLC, paying $50,000 in quarter two of 2025.
By August 2026, Jen Mallard, Vice President of Government Affairs, took the lead as an in-house lobbyist. BGR's lobbying team for WelbeHealth comprises Bob Wood as Chair and CEO, Brent Del Monte as Co-Head of Health and Life Sciences Practice, Raghav Aggarwal as Principal and Partner, and Chris Kelly as Vice President. Venn Strategies previously deployed Sam Goodstein as Managing Director of Federal Affairs, along with Kelly Ferguson as Vice President, Tyler Lazenby as Health Associate, and Samantha Campbell as Associate.
Broader Context
WelbeHealth operates Programs of All-Inclusive Care for the Elderly (PACE), a government-funded healthcare model serving individuals aged 55 and older who need nursing home-level care. The organization provides integrated medical and social services to seniors, addressing both acute and chronic healthcare needs alongside community-based support. PACE has emerged as a central focus in congressional debates over healthcare delivery for vulnerable elderly populations, particularly as policymakers seek to expand access to integrated care models that reduce institutional care costs while improving outcomes.
The August 2026 filing identifies three issue areas for WelbeHealth's federal advocacy: health issues, pharmacy policy, and science and technology matters. This broad portfolio reflects the organization's multifaceted interests in healthcare regulation, pharmaceutical reimbursement, and digital health infrastructure. The timing of WelbeHealth's lobbying registration coincides with ongoing congressional activity around healthcare delivery models and program reforms, particularly initiatives aimed at expanding integrated care access for seniors and veterans.
Bottom Line
WelbeHealth's entry into direct federal lobbying, supported by BGR Government Affairs' established health and life sciences practice, signals a strategic pivot toward proactive engagement with federal policymakers on issues central to PACE operations and integrated care delivery. By combining in-house advocacy capacity with external counsel experienced in complex healthcare policy, WelbeHealth is positioning itself to influence regulatory decisions and legislative initiatives affecting PACE program expansion, pharmacy reimbursement, and healthcare technology standards. The organization's focus on these three issue areas suggests it is preparing to navigate potential policy shifts in the Trump administration's healthcare agenda, particularly around program efficiency, cost containment, and the role of integrated care models in reducing Medicare and Medicaid expenditures.
Access the Legis1 platform for comprehensive political news, data, and insights
Spot something wrong? Report an issue with this article